RxDoctor Payments Data

Gary Friedlander, MD

Urology · Rockville, MDNPI 1083716195

Payments from drug & device makers

$10,401in general payments, 2019–2025

Across 363 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • AbbVie$1K
  • Astellas Pharma US Inc$824
  • Johnson & Johnson$717
  • Progenics Pharmaceuticals, Inc.$537
  • Boston Scientific$490
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$8939%
  • Food & beverage$8,77584%
  • Education$7337%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,401 in reported general payments places this provider in the 65th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$453,889
Medicare patients
1,103
Services billed
9,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron137$148,780
MyrbetriqMirabegron76$81,548
Tamsulosin Hcl851$24,974
Alfuzosin Hcl ErAlfuzosin Hcl503$12,741
Finasteride543$10,230
Dutasteride135$6,347
Silodosin59$6,015
Testosterone20$5,924
Methenamine Hippurate22$3,050
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl11$2,127
Oxybutynin Chloride ErOxybutynin Chloride56$2,045
Desmopressin Acetate22$1,970
Potassium Citrate ErPotassium Citrate21$1,859
Tolterodine Tartrate ErTolterodine Tartrate11$1,696
Estradiol16$1,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$469$148,780137 claims
Astellas Pharma US IncMyrbetriq$824$81,54876 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 274 urology providers in Maryland.

Other urology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →